Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rocket Pharmaceuticals Inc
(NQ:
RCKT
)
22.33
-0.50 (-2.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rocket Pharmaceuticals Inc
< Previous
1
2
3
Next >
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
February 07, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
January 13, 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Via
MarketBeat
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
January 09, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
December 22, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Completes Acquisition of Renovacor
December 01, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
November 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 12, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
October 10, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
October 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 03, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 30, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
September 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, STOR, RCKT, RCOR
September 22, 2022
Via
ACCESSWIRE
RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders
September 20, 2022
From
Halper Sadeh LLC
Via
Business Wire
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
September 20, 2022
From
Rocket Pharmaceuticals, Inc. and Renovacor, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 16, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
July 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 19, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 16, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
May 11, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
May 05, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
April 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.